Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 8Myeloid 7Plasma cell 3Dermatologic 2Classical hematology 2Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 16Radiosurgery 12Bevacizumab 12Radiotherapy 10Radiation 8pembrolizumab 6Specimen Handling 6Methotrexate 6Surgical Procedures, Operative 5Topotecan 4TIC10 compound 4Isotretinoin 4Carmustine 4Carboplatin 4abemaciclib 3Trastuzumab 3Thiotepa 3Standard of Care 3Nivolumab 3Magnetic Resonance Imaging 3Lomustine 3Irinotecan 3Erlotinib Hydrochloride 3Drug Therapy 3Dexamethasone 3vandetanib 2thymoglobulin 2temsirolimus 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Whole-Body Irradiation × CNS × Clear all
NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡